Instil Bio, Inc. (TIL) announced that the U.S. Food and Drug Administration has cleared an Investigational New Drug (IND) application for AXN-2510.
Instil Bio plans to initiate a phase 1 trial of 2510 as monotherapy for patients with relapsed/refractory solid tumors before the end of 2025.
The trial is designed to evaluate the safety of 2510 in patients with solid tumors. It also aims to assess the efficacy of the treatment.
Additionally, the study will examine the pharmacokinetics and pharmacodynamics of the drug.
